vimarsana.com

Page 190 - வாஷிங்டன் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Whole genome sequencing may guide blood cancer treatment

Whole genome sequencing may guide blood cancer treatment For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab tests to identify genetic changes. Some of these tests rely on technology that was invented more than 60 years ago and has been used clinically for the past three decades. Now, a new study from Washington University School of Medicine in St. Louis shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for a patient s blood cancer. Genome sequencing technology continuously is decreasing in cost and recently reached a level similar to that of conventional testing. In addition, results can be returned to patients in just a few days, making whole genome sequencing a potentially viable approach for determining the best treatment regimen for a particular patien

Pandemic inspired creative strategies for dating

This year we celebrated Passover early, on a Sunday a few days before St. Patrick’s Day. My adult children will disperse before the official holiday, but with the darkest days of the pandemic behind us, we have much to celebrate.

Promising role for whole genome sequencing in guiding blood cancer treatment | The Source

Sequencing results returned in a few days; costs similar to conventional testing A new study from Washington University School of Medicine shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for blood cancers, such as acute myeloid leukemia and myelodysplastic syndrome. (Photo: Getty Images) March 10, 2021 SHARE For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab tests to identify genetic changes. Some of these tests rely on technology that was invented more than 60 years ago and has been used clinically for the past three decades.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.